Regencell Bioscience Holdings Ltd
RGC evidence brief
What we can confirm
- Market Cap:
- $3.37B
What it means
What to watch
Prepared research question
What matters most for RGC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RGC
Regencell Bioscience Holdings Ltd (RGC) is a Hong Kong-based biopharmaceutical company developing Traditional Chinese Medicine treatments for neurocognitive disorders, with a recent net loss deepening and a plan to sell up to $500M in stock.
Key risk: Deepening net losses
Market Cap
$3.37B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2025.
Regencell Bioscience Holdings Ltd (RGC) is a Hong Kong-based biopharmaceutical company developing Traditional Chinese Medicine treatments for neurocognitive disorders, with a recent net loss deepening and a plan to sell up to $500M in stock.
- Hong Kong-based biopharmaceutical company developing Traditional Chinese Medicine (TCM) treatments for neurocognitive disorders [news · 2025-10-02].
- Reported a net loss of US$11.7 million for the full year ended June 30, 2026, compared to US$3.58 million the prior year [news · 2026-10-08].
- Filed a prospectus to sell up to $500 million in stock over time [news · 2026-03-30].
- Shareholders' equity of $4.9M as of 2025-06-30 [sec].
- Executed a 38:1 stock split effective June 16, 2025, driving a 4006% quarterly share price surge [news · 2025-06-21].
What works
- The company was added to the S&P Global BMI Index amid positive ADHD/ASD trial results, indicating some recognition in healthcare indices [news · 2025-10-02].
- Insider buying was noted, with the company topping a list of healthcare stocks with insider buying in 2025 [news · 2025-10-02].
What to weigh
- Net loss deepened to US$11.7 million for the year ended June 30, 2026, from US$3.58 million the prior year, with diluted loss per share rising to US$2.37 [news · 2026-10-08].
- Share price experienced extreme volatility, including a 19.8% drop on profit-taking after a 122% surge, attributed to a lack of catalysts [news · 2025-07-09].
- The company filed to sell up to $500 million in stock, which may dilute existing shareholders [news · 2026-03-30].
From the filings
Quoted directly from source documents.
Net loss deepened for the year ended June 30, 2026
“Regencell Bioscience Holdings (NasdaqCM:RGC) released full year results to June 30, 2026, reporting a net loss of US$11.7 million compared with US$3.58 million the prior year.”
News · October 8, 2026
Company is developing TCM treatments for neurocognitive disorders
“It is a Hong Kong-based biopharmaceutical company developing Traditional Chinese Medicine (TCM) treatments for neurocognitive disorders”
News · October 2, 2025
Risks & what to watch (3)›
Key risks
- Deepening net losses — Net loss increased to US$11.7M for FY2026 from US$3.58M prior year, indicating worsening financial performance [news · 2026-10-08].
- Potential shareholder dilution — Filing to sell up to $500M in stock could dilute existing shareholders [news · 2026-03-30].
- Extreme stock volatility — Share price experienced 19.8% drop after a 122% surge, with lack of catalysts noted [news · 2025-07-09].
What to watch
- Monitor the company's ability to reduce net losses and achieve profitability [news · 2026-10-08].
- Watch for any clinical trial updates or regulatory milestones for its TCM neurocognitive disorder treatments [news · 2025-10-02].
- Track the progress and impact of the $500M stock sale on share price and dilution [news · 2026-03-30].
Sources: News · PubMed · Generated October 13, 2026 · How we verify sources →
Run Regencell Bioscience Holdings Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Regencell Bioscience Holdings Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
31
Total value held
$15.7M
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 415,569 | $10.6M |
| marex group plc | 31,600 | $804K |
| vident advisory, llc | 29,588 | $752K |
| squarepoint ops llc | 26,613 | $677K |
| ubs group ag | 23,885 | $607K |
| morgan stanley | 20,078 | $511K |
| bank of america corp /de/ | 17,172 | $437K |
| state street corp | 11,851 | $301K |
| legal & general group plc | 9,903 | $252K |
| lpl financial llc | 8,596 | $219K |
Showing top 10 of 31 institutional holders of Regencell Bioscience Holdings Ltd. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 1.4%
- Days to cover
- 4.8
- Shares short
- 772,547
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RGC short interestFrequently asked questions
What is the AI investment thesis for Regencell Bioscience Holdings Ltd?
Regencell Bioscience Holdings Ltd (RGC) is a Hong Kong-based biopharmaceutical company developing Traditional Chinese Medicine treatments for neurocognitive disorders, with a recent net loss deepening and a plan to sell up to $500M in stock.
Who is the CEO of Regencell Bioscience Holdings Ltd?
Mr. Yat-Gai Au is the chief executive officer of Regencell Bioscience Holdings Ltd (RGC).
Where is Regencell Bioscience Holdings Ltd headquartered?
Regencell Bioscience Holdings Ltd (RGC) is headquartered in Causeway Bay, Hong Kong.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.